Trials / Active Not Recruiting
Active Not RecruitingNCT06993116
A Phase I Study of SHR-4712 in Patients With Advanced Solid Tumors
A Phase I Clinical Study on the Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-4712 in Patients With Advanced Solid Tumors
- Status
- Active Not Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 15 (actual)
- Sponsor
- Guangdong Hengrui Pharmaceutical Co., Ltd · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase 1, open label, first-in-human study to evaluate safety, tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), immunogenicity and anti-tumor activity of SHR-4712 in patients with advanced solid tumors. Patients will treat with SHR-4712 until unacceptable toxicity or disease progression.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR-4712 Injection | SHR-4712 injection. |
Timeline
- Start date
- 2025-06-09
- Primary completion
- 2027-05-01
- Completion
- 2027-05-01
- First posted
- 2025-05-28
- Last updated
- 2026-01-28
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT06993116. Inclusion in this directory is not an endorsement.